Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016).
Field | Value | Language |
dc.contributor.author | Daniels, Benjamin | |
dc.contributor.author | Kiely, Belinda E | |
dc.contributor.author | Lord, Sarah J | |
dc.contributor.author | Houssami, Nehmat | |
dc.contributor.author | Lu, Christine Y. | |
dc.contributor.author | Ward, Robyn L. | |
dc.contributor.author | Pearson, Sallie-Anne | |
dc.date.accessioned | 2021-09-15T05:50:07Z | |
dc.date.available | 2021-09-15T05:50:07Z | |
dc.date.issued | 2018 | en_AU |
dc.identifier.uri | https://hdl.handle.net/2123/26006 | |
dc.description.abstract | Patients treated with trastuzumab for HER2-positive metastatic breast cancer (HER2+MBC) are living longer, but there is little information on their outcomes and treatment experience beyond the median survival from clinical trials and real-world observational studies. We aim to describe the real-world treatment patterns and overall survival (OS) for women surviving five or more years from initiation of trastuzumab for HER2+MBC. This is a retrospective, whole-of-population cohort study of women initiating trastuzumab for HER2+MBC between 2001 and 2011, followed to 2016. We defined long-term survivors (LTS) as those patients surviving ≥ 5 years from trastuzumab initiation. We used dispensing claims to describe timing of cancer treatments used by LTS and to estimate time on and off HER2-targeted therapies, and OS from trastuzumab initiation for HER2+MBC. | en_AU |
dc.language.iso | en | en_AU |
dc.publisher | Springer Link | en_AU |
dc.relation.ispartof | Breast Cancer Research and Treatment | en_AU |
dc.rights | Copyright All Rights Reserved | en_AU |
dc.subject | HER2-positive | en_AU |
dc.subject | Metastatic breast cancer | en_AU |
dc.subject | Trastuzumab | en_AU |
dc.subject | HER2-targeted therapy | en_AU |
dc.subject | Long-term survival | en_AU |
dc.subject | Population-based | en_AU |
dc.title | Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016). | en_AU |
dc.type | Article | en_AU |
dc.subject.asrc | 1112 Oncology and Carcinogenesis | en_AU |
dc.subject.asrc | 1117 Public Health and Health Services | en_AU |
dc.identifier.doi | 10.1007/s10549-018-4804-0 | |
usyd.faculty | SeS faculties schools::Faculty of Medicine and Health::Sydney School of Public Health | en_AU |
usyd.citation.volume | 171 | en_AU |
usyd.citation.spage | 151 | en_AU |
usyd.citation.epage | 159 | en_AU |
workflow.metadata.only | Yes | en_AU |
Associated file/s
There are no files associated with this item.
Associated collections